International Pharmaceutical Industry Journal speaks with Edouard Pagnoud, Product Line Manager – Vial Stoppers at Aptar Pharma, about the evolving expectations ...

Holistic, risk-based contamination control and risk management expectations have evolved from a regional regulatory expectation to a globally recognised cornerst...

In recent years, drug discovery has advanced rapidly to yield increasingly sophisticated medicines, yet our primary method of administering these drugs remains r...

Parkinson's disease is a progressive neurological disorder that affects movement in the body. With a study published in Nature Medicine indicating that more than...

Central nervous system disorders present one of the greatest challenges in life sciences today. They are the Everest of medicine – stubborn, unyielding, awkward;...

For decades, nose-to-brain (N2B) drug delivery has offered an attractive proposition as a non-invasive means of reaching the central nervous system (CNS) while r...

Founded in 1995 in response to a growing need for outsourced pharmaceutical stability testing, A&M STABTEST has developed into a broad analytical service pro...

Converging Trends Driving Changes in Nasal Route Medicines Until about ten years ago nasal drug delivery was primarily associated with the treatment of local ...

Why converging regulation, sustainability and biologics are rewriting the specification for pharmaceutical materials – and why no company will solve it alone. ...